Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Han, Bobby Kwanghoon
Gaughan, John P.
Olsen, Nancy J.
Funding for this research was provided by: